BioCryst Pharmaceuticals is collaborating with Swixx BioPharma for Orladeyo (berotralstat) commercialisation in Central and Eastern Europe (CEE).

Under the deal, Swixx BioPharma will handle the commercialisation activities of oral therapy in 15 CEE markets.

The plasma kallikrein inhibitor Orladeyo has been specifically designed to prevent hereditary angioedema (HAE) attacks in adult and paediatric patients aged 12 years and above.

BioCryst Pharmaceuticals stated that the once-a-day Orladeyo capsule helps prevent HAE attacks by decreasing the plasma kallikrein activity.

The therapy has already received approval in the US and many other markets worldwide.

BioCryst chief commercial officer Charlie Gayer said: “We continue to build partnerships with companies that have deep expertise in commercialising rare disease therapies as we advance our mission of bringing ORLADEYO to patients living with hereditary angioedema around the world.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The team at Swixx is highly skilled at launching rare disease therapies in Central and Eastern Europe, and we are thrilled to work alongside them to bring our oral, once-daily prophylactic treatment for HAE to patients in this region.”

Back pain, gastroesophageal reflux disease, vomiting, abdominal pain, and diarrhoea are the most common adverse reactions observed in patients receiving Orladeyo.

Swixx BioPharma offers end-to-end services to its partner companies for bringing therapies to treat rare diseases.

Swixx CEO Jean-Michel Lespinasse said: “Based on our unrivalled understanding of the rare disease landscape in CEE, we believe we are best suited to help BioCryst bring Orladeyo to patients living with HAE in the countries within this region.”